Photo by mbicca from unsplash
NVL-520, a selective macrocyclic inhibitor of ROS1, demonstrated antitumor activity in patient case studies of ROS1 inhibitor–refractory lung cancers without observed neurologic toxicities attributed to TRK inhibition. Click to show full abstract
NVL-520, a selective macrocyclic inhibitor of ROS1, demonstrated antitumor activity in patient case studies of ROS1 inhibitor–refractory lung cancers without observed neurologic toxicities attributed to TRK inhibition.
Keywords:
inhibitor ros1;
nvl 520;
selective trk;
520 selective;
inhibitor
Journal Title: Cancer Discovery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Discovery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!